title: Treatment of bone metastasis in prostate cancer: efficacy of a novel polybisphosphonate.
abstract: OBJECTIVE
  To investigate the in vivo efficacy of a novel polybisphosphonate (ODX) in the treatment of bone metastasis from prostate cancer.
  
  
  METHODS
  A rat prostatic carcinoma model was used. Forty-two rats (21 control, 21 treatment) had induction of bone lesions through injection of AT6.1 cells into the distal medullar cavity of long bones (right femur). At day 21 post injection, radiographs were taken and tumor score (severity of lesions, 0-4) and tumor incidence (score >0) were determined. Treatment started at day 23 and lasted until day 49 (four i.v. administrations of ODX during four weeks).
  
  
  RESULTS
  ODX reduced the severity of the lesions compared to the control group. Forty-seven percent of the treated rats had regression of their lesions at the study end, including four rats showing disappearance of the lesions i.e. score 0. Osteocondensation at the growth plate was only observed in the treatment group, indicating osteoclast inhibition.
  
  
  CONCLUSIONS
  In spite of a relatively short treatment period with only four administrations, ODX showed significant efficacy (p=0.0023), with inhibition of tumor progression and osteolysis. The results are encouraging, confirming previous in vitro studies. Clinical research is pending on patients with bone metastasis from castration-resistant prostate cancer.
authors.affiliation: Atlantic Bone Screen, Nantes, France.
authors.forename: Florence
authors.initials: F
authors.lastname: Daubine
authors.forename: Ronan
authors.initials: R
authors.lastname: LE Bot
authors.forename: Marcela
authors.initials: M
authors.lastname: Márquez
authors.forename: Sten
authors.initials: S
authors.lastname: Nilsson
authors.forename: Torbjörn
authors.initials: T
authors.lastname: Schröder
authors.forename: Anders R
authors.initials: AR
authors.lastname: Holmberg
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D004164:Diphosphonates / Q000494:pharmacology*; D018450:Disease Progression; D015195:Drug Design; D005269:Femur / Q000473:pathology; D008297:Male; D009362:Neoplasm Metastasis; D009368:Neoplasm Transplantation; D010014:Osteolysis; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000473:pathology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013997:Time Factors
chemical_list: D000970:Antineoplastic Agents; D004164:Diphosphonates